BiomeDx advances to finals of EIT Health Catapult Program 2022-2023
VIENNA, 3rd April 2023:
BiomeDx has been selected as a finalist in the prestigious EIT Health Catapult program in the medtech category. The program is designed to support innovative healthcare startups by providing them with mentorship, networking opportunities, and funding.
BiomeDx’s selection as a finalist in the EIT Health Catapult program is a testament to the company’s dedication to developing cutting-edge diagnostic tools for gut microbiome analysis. The innovative approach to gut microbiome analysis has the potential to revolutionize the field of personalized medicine and change the way how we treat cancer. Their participation in the EIT Health Catapult program is a significant step towards achieving their goal of bringing their technology to patients and healthcare providers.
The company is grateful for the opportunity to participate in the EIT Health Catapult program and looks forward to sharing their vision with the community. Stay tuned for more news about BiomeDx’s progress in the finals at the Bits & Pretzels Health Tech conference in Munich between 20-21 June.